Related Experiment Videos
Neonatal and maternal platelets: activation at time of birth
C R Suarez1, J Gonzalez, C Menendez
1Loyola University Stritch School of Medicine, Department of Pediatric Hematology/Oncology, Maywood, Illinois.
Insights
Newborns and mothers show significant platelet activation at birth, indicated by elevated beta-thromboglobulin (BTG), thromboxane B2 (TxB2), and platelet factor 4 (PF4). This may explain transient neonatal platelet dysfunction.
Area of Science:
- Neonatal physiology
- Hematology
- Platelet biology
Background:
- Platelet activation markers are crucial for understanding hemostasis.
- Neonatal hemostasis differs from adult hemostasis, with potential for platelet dysfunction.
Purpose of the Study:
- To determine plasma concentrations of platelet activation markers in newborns and their mothers at birth.
- To investigate the relationship between mode of delivery and platelet activation.
- To explore the potential link between platelet activation and transient neonatal platelet dysfunction.
Main Methods:
- Measurement of plasma beta-thromboglobulin (BTG), thromboxane B2 (TxB2), and platelet factor 4 (PF4) at birth.
- Ultrastructural examination of platelets.
- Comparison of marker levels between newborns and mothers, and across different delivery modes.
Main Results:
- Significant elevation of BTG, TxB2, and PF4 in both newborns and mothers at birth.
- Elevated TxB2 levels in newborns suggest a functional platelet prostaglandin pathway.
- No significant influence of delivery mode (vaginal vs. caesarean) on platelet activation.
- No morphological differences observed between maternal and newborn platelets.
Conclusions:
- Marked activation of both maternal and newborn platelet systems occurs at birth.
- This activation may contribute to the transient platelet dysfunction observed in newborns.
- Further research is warranted to elucidate the mechanisms and implications of neonatal platelet activation.
Abstract:
Determination of the plasma concentrations of beta-thromboglobulin (BTG), thromboxane B2 (TxB2) and platelet factor 4 (PF4) were made at the time of birth in 18 newborns and their respective mothers. Both groups show significant elevation of all these molecular markers, suggesting marked platelet activation. The elevated TxB2 levels in the newborn group, 25 +/- 8 pg/ml, are compatible with a normally functioning and activated platelet prostaglandin pathway. Mode of delivery, vaginal or caesarean section, does not significantly influence the degree of activation in either group. Ultrastructural platelet examination did not reveal any morphologic differences between maternal and newborn platelets. There appears to be marked activation of the newborn and maternal platelet systems at the time of birth, and we postulate that this may explain in part the transient platelet dysfunction observed in newborns.